RADDISH
LIVE

Serial Number

98116944

Owner

Global Alzheimer's Platform Foundation Inc.

Attorney

Christopher A. Proskey

First Use Date

Jun 30, 2025

Filing Date

Aug 4, 2023

Add to watchlist:

No watchlists yet
View on USPTO

RADDISH Trademark

Serial Number: 98116944 • Registration: 8254423

RADDISH is a trademark filed by Global Alzheimer's Platform Foundation Inc. on August 4, 2023. The trademark is classified under Class 36 (Insurance & Financial), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Global Alzheimer's Platform Foundation Inc. (15 trademarks)

1101 K Street NW, Suite 400
Washington, DC 20005

Entity Type: 03

Trademark Details

Filing Date

August 4, 2023

Registration Date

May 12, 2026

First Use Anywhere

June 30, 2025

First Use in Commerce

June 30, 2025

Published for Opposition

August 20, 2024

Goods & Services

Promoting public awareness of Alzheimer's, neurodegenerative diseases and other neurological and central nervous system diseases and issues related thereto in the nature of patient registries, patient research, patient advocacy and patient fundraising efforts; Promoting public awareness of health care issues for patients with Alzheimer's, neurodegenerative diseases and other neurological and central nervous system diseases, and the importance of patient registration on Alzheimer's, neurodegenerative diseases and other neurological and central nervous system disease registries; Charitable services, namely, organizing and developing programs that aim to improve the lives of patients with Alzheimer's, neurodegenerative diseases and other neurological and central nervous system disease patients, their caregivers and families; Charitable business services, namely, administration of programs for enabling participants to receive services for Alzheimer's, neurodegenerative diseases and other neurological and central nervous system disease patients, their caregivers and families; Business services, namely, recruitment of participants for neuroscience clinical research; Maintaining a registry of participants for neuroscience clinical research relating to the treatment and prevention of brain disease; Promoting participation in clinical trials and research in the neuroscience field; Recruitment advertising services, namely, advertising clinical trials for the purpose of recruiting patients and placing patients for participation in clinical trials in the neuroscience field

Charitable fundraising; Charitable fundraising for Alzheimer's disease and neurodegenerative disease research and treatment

Scientific research in the nature of conducting clinical trials and research for others in the field of Alzheimer's, neuro degenerative diseases and other neurological and central nervous system diseases; Medical and scientific research, namely, conducting clinical trials for others; Medical and scientific research, namely, conducting clinical trials for patients with Alzheimer's, neurodegenerative diseases and other neurological and central nervous system diseases

Healthcare services; Healthcare services, namely, administering care to patients; Healthcare services, namely, administering care to patients with Alzheimer's, neurodegenerative diseases and other neurological and central nervous system diseases; Healthcare services, namely, administering tests for patients with Alzheimer's, neurodegenerative diseases and other neurological and central nervous system diseases; Healthcare services, namely, taking samples from patients with Alzheimer's, neurodegenerative diseases and other neurological and central nervous system diseases; Establishing tissue, bloods, organ, and stem cell bank of biological samples related to Alzheimer's neurodegenerative diseases and other neurological and central nervous system diseases; Providing health screening services in the field of Alzheimer's, neurodegenerative diseases, and other neurological and central nervous system diseases; Providing health screening services related to Alzheimer's, neurodegenerative diseases and other neurological and central nervous system diseases

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 12, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
May 12, 2026 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Apr 17, 2026 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Apr 17, 2026 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Apr 1, 2026 SUPC
USE AMENDMENT FILED
Oct 14, 2025 IUAF
TEAS STATEMENT OF USE RECEIVED
Oct 14, 2025 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 12, 2025 EXRA
SOU EXTENSION 1 GRANTED
Apr 12, 2025 EX1G
SOU EXTENSION 1 FILED
Apr 11, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 11, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 15, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 20, 2024 NPUB
PUBLISHED FOR OPPOSITION
Aug 20, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 31, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 17, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 16, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 16, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 16, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 16, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 8, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 8, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 8, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 8, 2024 GNRN
NON-FINAL ACTION E-MAILED
Apr 8, 2024 GNRT
NON-FINAL ACTION WRITTEN
Apr 8, 2024 CNRT
ASSIGNED TO EXAMINER
Apr 5, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 3, 2023 NWOS
NEW APPLICATION ENTERED
Aug 8, 2023 NWAP